In vitro Characterization of Anti-SARS-CoV-2 Intravenous Immunoglobulins (IVIg) Produced From Plasma of Donors Immunized With the BNT162b2 Vaccine and Its Comparison With a Similar Formulation Produced From Plasma of COVID-19 Convalescent Donors

In vitro Characterization of Anti-SARS-CoV-2 Intravenous Immunoglobulins (IVIg) Produced From Plasma of Donors Immunized With the BNT162b2 Vaccine and Its Comparison With a Similar Formulation Produced From Plasma of COVID-19 Convalescent Donors

Despite vaccines are the main strategy to control the ongoing global COVID-19 pandemic, their effectiveness could not be enough for individuals with immunosuppression. In these cases, as well as in patients with moderate/severe COVID-19, passive immunization with anti-SARS-CoV-2 immunoglobulins coul...

Full description

Bibliographic Details
Main Authors: Gabriel Rojas-Jiménez, Daniela Solano, Álvaro Segura, Andrés Sánchez, Stephanie Chaves-Araya, María Herrera, Mariángela Vargas, Maykel Cerdas, Gerardo Calvo, Jonathan Alfaro, Sebastián Molina, Kimberly Bolaños, Andrés Moreira-Soto, Mauren Villalta, Adriana Sánchez, Daniel Cordero, Gina Durán, Gabriela Solano, Aarón Gómez, Andrés Hernández, Laura Sánchez, Marco Vargas, Jean Felix Drexler, Alberto Alape-Girón, Cecilia Díaz, Guillermo León
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Medical Technology
Subjects:
BNT162b2 vaccine
convalescent plasma
COVID-19
hyperimmune plasma
hyperimmune polyclonal antibodies
IVIg
Online Access:https://www.frontiersin.org/articles/10.3389/fmedt.2021.772275/full

Similar Items

Similar Items